Cancer Treatment and Research Communications

SJR Rank #4,947H-index: 35SJR: 0.995Best quartile: Q2Open AccessAPC: US$2,740Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

Elsevier Ltd

Country

United Kingdom

Type

journal

SJR by Edition

2022202500.250.50.751

Subject Categories

  • Cancer ResearchQ2
  • OncologyQ2

Areas: Biochemistry, Genetics and Molecular Biology · Medicine

Most published research topics

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersLung Cancer Research StudiesBreast Cancer Treatment StudiesCancer Genomics and DiagnosticsHER2/EGFR in Cancer ResearchGlobal Cancer Incidence and ScreeningColorectal Cancer Treatments and StudiesFerroptosis and cancer prognosis

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs090180270360

Documents per Year

2022202504080120160

Detailed Information

ISSN

2468-2942

SJR Best Quartile

Q2

Region

Western Europe

Citations per Document (2 years)

3.49

References per Document

49.16

Coverage

2016-2026

Scope

From January 2020 Cancer Treatment and Research Communications is an open access journal. Authors who publish in Cancer Treatment and Research Communications will be able make their work immediately, permanently, and freely accessible. Cancer Treatment and Research Communications authors will pay an article publishing charge (APC), have a choice of license options, and retain copyright to their published work. Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.

Metrics from SCImago Journal Rank 2025. View on SCImago